A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

Stopped Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.

Conditions

• Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

• DRUG: SLC-0111
• DRUG: Gemcitabine Injection

Sponsor

British Columbia Cancer Agency

Collaborators

• [object Object]
• [object Object]